Siga Technologies (NSDQ:SIGA) said today that it signed a multi-year contract with the Biomedical Advanced Research & Development Authority to provide oral and intravenous versions of Siga’s Tpoxx smallpox treatment to the Strategic National Stockpile. The contract, which is valued at up to $629 million, also includes funding for advanced development of the the drug’s IV […]
sigatechnologies
Siga wins FDA nod for oral smallpox treatment
Siga Technologies (NSDQ:SIGA) today won FDA approval for its oral formulation of tecovirimat as a treatment of smallpox in the case of a potential outbreak. The drug is designed to mitigate the impact of a potential bioterrorism attack, according to the New York-based company. Siga also touted that the FDA granted its request for a priority […]
Siga Technologies touts pivotal data for oral smallpox therapy
Siga Technologies (NSDQ:SIGA) said today that data from a pivotal human safety study and animal efficacy studies of its oral smallpox therapy were published in the New England Journal of Medicine. Data from the studies support the efficacy and favorable safety profile of Tpoxx, an oral formulation of tecovirimat. “Smallpox is both highly contagious and highly […]
